====== Coalition for Epidemic Preparedness Innovations ======

{{ ::cepi-logo-colour_1_.png?200|}}

The **Coalition for Epidemic Preparedness Innovations (CEPI)** is a supra-governmental organization based in [[norway:Oslo]], [[Norway]]. It operates as a [[public-private partnership]], soliciting donations from governments, corporations, charities, foundations and individuals to finance research projects to develop [[vaccines]] against [[emerging infectious diseases]] (EID).

CEPI operates out of three offices across Oslo, [[united_kingdom:England:London]] and [[united_states:Washington, D.C.]]

===== History =====

==== Formation ====

In July 2015, a paper outlining an idea for a new global funding mechanism for [[vaccine]] development was published in the [[New England Journal of Medicine]] (NEJM) written by [[Jeremy Farrar]], [[Stanley Plotkin]] and [[Adel Mahmoud]].((Plotkin, S. A., Mahmoud, A. A. F., & Farrar, J. (2015). //Establishing a Global Vaccine-Development Fund.// New England Journal of Medicine, 373(4), 297–300. https://doi.org/10.1056/nejmp1506820)) Their concept was further expanded at the 2016 [[World Economic Forum]] in [[switzerland:Davos]], [[Switzerland]], where it was discussed as a solution to the problems encountered in developing and distributing a vaccine for the Western African [[Ebola]] virus epidemic.((//CEPI officially launched.// (2017, January 18). CEPI. https://archive.ph/genb4))

CEPI was officially launched on January 18, 2017 at the WEF, funded by initial donations of $100 million each from the [[Bill & Melinda Gates Foundation]] and [[Wellcome Trust]], with an additional $260 million pledged by a coalition of the governments of [[Germany]], [[Japan]] and [[Norway]].((Solberg, E. (2017, January 20). //$460 Million Coalition for Epidemic Preparedness Innovation Launched.// Philanthropy News Digest. https://web.archive.org/web/20220112055033/https://philanthropynewsdigest.org/news/460-million-coalition-for-epidemic-preparedness-innovation-launched)) The government of [[India]] also served as a co-founder, contributing funding at a later date.((Paton, J. (2017, January 18). //Ebola, Zika Push Drugmakers Into Effort to Avert Pandemics.// Bloomberg. https://web.archive.org/web/20221020002146/https://www.bloomberg.com/news/articles/2017-01-18/ebola-zika-push-drugmakers-to-join-effort-to-avert-pandemics))

==== Additional Funding ====

In January 2022, [[Wellcome Trust]] and the [[Bill & Melinda Gates Foundation]] pledged an additional $150 million each to CEPI.((//Wellcome, Gates pledge $300 million to prevent future epidemics.// (2022, January 20). Philanthropy News Digest. https://web.archive.org/web/20220120223745/https://philanthropynewsdigest.org/news/wellcome-gates-pledge-300-million-to-prevent-future-epidemics))

===== Organization =====

==== Personnel ====

^  Leadership((//Who we are.// CEPI. Retrieved October 19, 2022, from https://web.archive.org/web/20221019165747/https://cepi.net/about/whoweare/))  ^^^
^ Name  ^ Position  ^ Affiliation(s)  ^
| [[Astrid Helgeland]]  | Director of Human Resources  | [[Norwegian Institute of International Affairs]], [[Norwegian Institute of Public Health]], [[World Bank]]((//Astrid Helgeland.// LinkedIn. Retrieved October 19, 2022, from www.linkedin.com/in/astrid-helgeland-a9778239/))  |
| [[Emma Wheatley]]  | Director of Access and Private Partnerships, Deputy General Council  | [[Biomedical Advanced Research and Development Authority]] (BARDA), [[pharmaceutical_companies:Emergent BioSolutions]], [[University of Oxford]]  |
| [[Fernando Pons]]  | Chief Operating Officer (COO)  | [[ED&F Man]], [[European Bank for Reconstruction and Development]] (EBRD), [[ExxonMobil]], [[pharmaceutical_companies:Merck]], [[Rio Tinto]]  |
| [[Frederik Kristensen]]  | Deputy CEO  | [[Norwegian Agency for Development Cooperation]], [[UNICEF]], [[United Nations Population Fund]] (UNFPA), [[World Health Organization]]  |
| [[Ingrid Kromann]]  | Acting Executive Director of Manufacturing and Supply Chain  | [[Statens Serum Institut]]  |
| [[Joseph Simmonds-Issler]]  | Chief of Staff  | [[COVAX]], [[Johns Hopkins Center for Health Security]], [[Wellcome Trust]]  |
| [[Luc Debruyne]]  | Strategic Advisor to the CEO  | [[pharmaceutical_companies:GlaxoSmithKline]]  |
| [[Mads Høgholen]]  | Director of Finance and Operations  | [[pharmaceutical_companies:Abbott]], [[pharmaceutical_companies:AbbVie]], [[Arthur Andersen]], [[Ernst & Young]]  |
| [[Magnus Holme]]  | Director of Governance, Risk and Compliance  | [[Codex Advokat]], [[Namsfogden]], [[Securitas Norge]], [[Storebrand]]((Magnus Holme. LinkedIn. Retrieved October 19, 2022, from https://www.linkedin.com/in/magnus-holme-18537110/))  |
| [[Melanie Saville]]  | Executive Director of Vaccine Research & Development  | [[COVAX]], [[pharmaceutical_companies:Janssen]], [[pharmaceutical_companies:Sanofi Pasteur]], [[pharmaceutical_companies:Wyeth]]  |
| [[Monina Vierneza]]  | General Counsel and Head of Legal  | [[General Electric]], [[pharmaceutical_companies:Novartis]], [[pharmaceutical_companies:Pfizer]]  |
| [[Nicole Lurie]]  | Executive Director of Preparedness and Response  | [[American College of Physicians]], [[Association for Health Services Research]] (AHSR), [[Institute of Medicine]], [[Society of General Internal Medicine]], [[United States Department of Health and Human Services]]((//Reopen DC Co-Chair | Nicole Lurie.// Government of the District of Columbia. Retrieved October 20, 2022, from https://archive.ph/4t2xQ))  |
| [[Rachel Grant]]  | Executive Director of Communications and Advocacy  | [[McKinsey & Company]], [[Tony Blair]]  |
| [[Richard Hatchett]]  | CEO  | [[Biomedical Advanced Research and Development Authority]] (BARDA), [[Homeland Security Council]], [[National Security Council]]  |
| [[Samia Saad]]  | Executive Director of Resource Mobilisation & Investor Relations  | [[Bill & Melinda Gates Foundation]], [[BioIndustry Association]] (BIA), [[Harvard Medical School]], [[King's College London]], [[World Health Organization]]  |
| [[Stephen Mayhew]]  | Director of Strategy & Portfolio  | [[pharmaceutical_companies:GlaxoSmithKline]], [[pharmaceutical_companies:Stallergenes Greer]]  |
^  Board of Directors  ^^^
| [[Anita Zaidi]]  | Board member  | [[Aga Khan University]], [[Bill & Melinda Gates Foundation]], [[National Academy of Medicine]], [[National Foundation for Infectious Diseases]], [[WomenLift Health]]  |
| [[Cherry Gagandeep Kang]]  | Board member  | [[Baylor College of Medicine]], [[Christian Medical College Vellore]], [[Health Protection Agency]], [[Johns Hopkins Bloomberg School of Public Health]], [[Tufts University School of Medicine]]  |
| [[Cyrus Ardalan]]  | Board member  | [[Alvarez & Marsal]], [[Barclays]], [[BNP Paribas]], [[Charities Aid Foundation]], [[Citi]], [[Dubai International Financial Group]], [[Humanitarian Finance Forum]], [[International Capital Markets Association]] (ICMA), [[International Financing Facility for Immunization]], [[LXiREIT]], [[OakNorth Bank]], [[RockCreek]], [[World Bank]]  |
| [[David Reddy]]  | Board member  | [[Medicines for Malaria Venture]], [[pharmaceutical_companies:Roche]]  |
| [[Githinji Gitahi]]  | Board member  | [[Africa Centres for Disease Control and Prevention]], [[Amref Health Africa]], [[Commission on African COVID-19 Response]], [[UCH2030]], [[Unilever]]  |
| [[L. Rizka Andalycia]]  | Board member  | [[Association of Southeast Asian Nations]] (ASEAN), [[Indonesian Food and Drug Administration]], [[International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use]] (ICH), [[Ministry of Health Republic of Indonesia]]  |
| [[Ichiro Kurane]]  | Board member  | [[National Institute of Infectious Diseases]]  |
| [[Jane Halton]]  | Board member  | [[Australian and New Zealand Banking Group]] (ANZ Bank), [[Australian Department of Finance]], [[Australian Department of Health]], [[Australian Strategic Policy Institute]], [[Clayton Utz]], [[National Academy of Medicine]], [[Organisation for Economic Co-operation and Development]] (OECD), [[University of Canberra]], [[University of Sydney]], [[World Health Assembly]], [[World Health Organization]]  |
| [[Nísia Trindade Lima]]  | Board member  | [[Brazilian Academy of Sciences]], [[Brazilian Unified Health System]], [[COVID-19 Global Research & Innovation Forum]], [[Fiocruz]], [[Gender Summit]], [[High-Level Political Forum on Sustainable Development]], [[Institute for Social and Political Studies]], [[Lancet COVID-19 Committee]], [[Nairobi Summit]], [[Solidarity Trial]], [[State University of Rio de Janeiro]], [[United Nations]], [[World Health Organization]], [[ZIKAlliance]]  |
| [[Samba Sow]]  | Board member  | [[American Society of Tropical Medicine and Hygiene]], [[Center for Vaccine Development - Mali]] (CVD-Mali), [[Ministry of Public Health and Hygiene]], [[World Health Organization]]  |
| [[Rajeev Venkayya]]  | Board member  | [[pharmaceutical_companies:Aerium Therapeutics]], [[Bill & Melinda Gates Foundation]], [[Gavi|Gavi, the Vaccine Alliance]], [[International AIDS Vaccine Initiative]], [[National Security Council Directorate for Global Health Security and Biodefense]], [[pharmaceutical_companies:Takeda]]  |
| [[Veronika von Messling]]  | Board member  | [[Duke-NUS Medical School]], [[German Federal Ministry of Education and Research]] (BMBF), [[INRS Armand-Frappier Health and Biotechnology Centre]], [[Paul-Ehrlich-Institute]]  |
| [[Emmanuel Hanon]]  | Non-voting board member  | [[pharmaceutical_companies:GlaxoSmithKline]], [[medical_technology_companies:Viome]]  |
| [[Juan Pablo Uribe]]  | Non-voting board member  | [[Global Financing Facility for Women, Children and Adolescents]], [[Ministry of Health and Social Protection]], [[World Bank]]  |
| [[Margaret Hamburg]]  | Non-voting board member  | [[American Association for the Advancement of Science]] (AAAS)  |
| Richard Hatchett  | Non-voting board member  | -  |
| [[Soumya Swaminathan]]  | Non-voting board member  | [[World Health Organization]]  |
^  Other committee members  ^^^
| [[Alex Cebotari]]  | Non-voting member  | [[World Bank]]  |
^  Scientific Advisory Committee  ^^^
| [[Alan Barrett]]  | -  | [[Sealy Institute for Vaccine Sciences]] (SCVD)  |
| [[Alash'le Abimiku]]  | -  | [[Institute of Human Virology Nigeria]] (IHVN)  |
| [[Azra Ghani]]  | -  | [[Imperial College London]]  |
| [[Christian Drosten]]  | -  | [[Institute of Virology-Charité]]  |
| [[Dominique Maugeais]]  | -  | -  |
| Emmanuel Hanon  | Chair  | -  |
| [[Frances Priddy]]  | -  | [[Vaccine Alliance Aoteroa New Zealand]], [[Malaghan Institute of Medical Research]]  |
| [[Gary Nabel]]  | -  | [[pharmaceutical_companies:Modex Therapeutics]]  |
| [[George Gao]]  | -  | [[Chinese Center for Disease Control and Prevention]]  |
| [[Inger Damon]]  | -  | [[Centers for Disease Control and Prevention]] (CDC)  |
| [[Josie Golding]]  | -  | [[Wellcome Trust]]  |
| [[Ken Ishii]]  | -  | [[Institute of Medical Research]] at the [[University of Tokyo]]  |
| [[Kent Kester]]  | -  | [[pharmaceutical_companies:Sanofi Pasteur]]  |
| [[Laura Palomares]]  | -  | [[Instituto de Biotecnologa UNAM]]  |
| [[Linfa Wang]]  | -  | [[Duke-NUS Medic School]]  |
| [[Luciana Borio]]  | -  | [[Council on Foreign Relations]]  |
| [[Mahmudur Rahman]]  | -  | -  |
| [[Marc Lipsitch]]  | -  | [[Harvard T.H. Chan School of Public Health]]  |
| [[Marco Safadi]]  | -  | [[Santa Case de Sao Paulo School of Medical Sciences]]  |
| [[Michael King]]  | Vice-chair  | -  |
| [[Michel De Wilde]]  | -  | [[pharmaceutical_companies:Acambis]], [[pharmaceutical_companies:BIOASTER]], [[Chinese Vaccinology Course]], [[COVAX]], [[pharmaceutical_companies:CureVac]], [[pharmaceutical_companies:GlaxoSmithKline]], [[Human Immunome Project]], [[Infectious Disease Research Institute]], [[MDW Consultant]], [[pharmaceutical_companies:Sanofi Pasteur]], [[pharmaceutical_companies:Univercells]], [[pharmaceutical_companies:VaxDesign]], [[pharmaceutical_companies:VBI Vaccines]]  |
| [[Paula Bryant]]  | -  | [[National Institute of Allergy and Infectious Diseases]] (NIAID)  |
| [[Peter Dull]]  | -  | [[Bill & Melinda Gates Foundation]]  |
| [[Peter Paradiso]]  | -  | [[Paradiso Biologics Consulting]]  |
| [[Peter Smith]]  | -  | [[London School of Hygiene & Tropical Medicine]]  |
| [[Phil Krause]]  | -  | [[Food and Drug Administration]] (FDA)  |
| [[Rebecca Grais]]  | -  | [[Epicentre]]  |
| [[Rino Rappuoli]]  | -  | [[pharmaceutical_companies:GlaxoSmithKline]]  |
| [[Sani Aliyu]]  | -  | [[Nigeria Presidential Task Force on COVID-19]]  |
| [[Stanley Plotkin]]  | -  | [[University of Pennsylvania]]  |
| [[Stephen Thomas]]  | -  | [[SUNY Upstate Medical University]]  |
| [[V. Krishna Mohan]]  | -  | [[pharmaceutical_companies:Bharat Biotech]]  |
| [[Vaseeharan Sathiyamoorthy]]  | -  | [[World Health Organization]]  |
| [[Vineeta Bal]]  | -  | [[Indian Institute of Science Education and Research]]  |

==== Joint Coordination Group ====

The Joint Coordination Group (JCG) is made up of organizations with an interest in the development and deployment of [[vaccines]] through CEPI's activities. Its members include:

  * [[African Vaccine Regulatory Forum]] (AVAREF)
  * [[European Medicines Agency]] (EMA)
  * [[Food and Drug Administration]] (FDA)
  * [[Gavi|Gavi, the Vaccine Alliance]]
  * [[International Federation of Red Cross and Red Crescent Societies]] (IFRC)
  * [[Médecins Sans Frontières]] (MSF)
  * [[National Institute for Biological Standards and Control]] (NIBSC)
  * [[UNICEF]]
  * [[Wellcome Trust]]
  * [[World Health Organization]] (WHO)
==== Funding ====

To date, CEPI has secured financial support from [[Australia]], [[Austria]], [[Belgium]], the [[Bill & Melinda Gates Foundation]], [[Canada]], [[Denmark]], the [[European Commission]], [[Ethiopia]], [[Finland]], [[Germany]], [[Greece]], [[Hungary]], [[Iceland]], [[Indonesia]], [[Italy]], [[Japan]], [[Kuwait]], [[Lithuania]], [[Luxembourg]], [[Malaysia]], [[Mexico]], [[Netherlands]], [[New Zealand]], [[Norway]], [[Portugal]], [[Romania]], [[Saudi Arabia]], [[Serbia]], [[Singapore]], [[South Korea]], [[Switzerland]], [[United Kingdom]], the [[United States Agency for International Development]] (USAID), and [[Wellcome Trust]].

CEPI has also received support from private sector entities as well as public contributions through the [[United Nations Foundation]]'s [[COVID-19 Solidarity Response Fund]].

As of July 2022, CEPI has received $2.3 billion USD from governments and $282.35 million from private investors, for a total of $2.6 billion. An additional $1.28 billion has been pledged for future donation.

^  Private investors((//Investment Overview.// (2022). CEPI. https://web.archive.org/web/20220829190949/https://cepi.net/wp-content/uploads/2022/02/2022_07_06-CEPI-Investment-Overview.pdf))  ^^^
^ Name  ^ Contributions (USD)  ^ Pledges (USD)  ^
| [[Avast]]  | $8,000,000  | -  |
| [[Bill & Melinda Gates Foundation]]  | $121,400,000  | $154,000,000  |
| [[Fidelity]]  | $1,490,000  | -  |
| [[Goldman Sachs]]  | $1,630,000  | -  |
| [[Nestlé]]  | $1,040,000  | -  |
| [[Sumitomo Mitsui Banking Corporation]]  | $1,140,000  | -  |
| [[Paul G. Allen Family Foundation]]  | $3,500,000  | -  |
| [[COVID-19 Solidarity Response Fund]]  | $10,000,000  | -  |
| [[Wellcome Trust]]  | $130,900,000  | $150,000,000  |
| Others (less than $1 million)  | $3,240,000  | -  |
===== Activities =====

==== Research ====

CEPI and the [[Canadian Institutes of Health Research]] co-administer the CIHR-CEPI Leadership Award for Excellence in Vaccine Research for Infectious Diseases of Epidemic Potential.((Canadian Institutes of Health Research. (2021, January 18). //Pre-announcement: CIHR-CEPI Leadership Award for Excellence in Vaccine Research for Infectious Diseases of Epidemic Potential - CIHR.// Government of Canada. https://archive.ph/viORE))

==== Portfolio ====

CEPI's vaccine portfolio includes:((//Our portfolio.// CEPI. Retrieved October 21, 2022, from https://web.archive.org/web/20221021070613/https://cepi.net/research_dev/our-portfolio/))

^ Company  ^ Description  ^ CEPI funding  ^ Notes  ^
| [[pharmaceutical_companies:SK Bioscience]]  | Broadly Protective [[Coronavirus]] Vaccine  | Up to $50 million USD  | [[Nanoparticle]] vaccine platform (preclinical) |
| [[pharmaceutical_companies:SK Bioscience]] | [[COVID-19]]  | Up to $210 million USD  | [[Recombinant protein]] (approved for use in [[South Korea]])  |
| [[pharmaceutical_companies:Codiak Biosciences]]  | Broadly Protective Coronavirus Vaccine  | Up to $2.5 million USD  | [[exoVACC]] platform (preclinical)  |
| [[Centre for Process Innovation]] (CPI), [[California Institute of Technology]], [[University of Oxford]], [[pharmaceutical_companies:Ingenza]] | Broadly Protective Coronavirus Vaccine  | Up to $30 million USD  | [[Mosaic-8]] nanoparticle (preclinical) |
| [[pharmaceutical_companies:Bharat Biotech]], [[University of Sydney]], [[pharmaceutical_companies:ExcellGene]]  | Broadly Protective Coronavirus Vaccine  | Up to $12.5 million USD  | Modified trimeric spike (preclinical)  |
| [[pharmaceutical_companies:MigVax]]  | Broadly Protective Coronavirus Vaccine  | Up to $4.3 million USD  | Subunit vaccine tablet (preclinical)  |
| [[Vaccine and Infectious Disease Organization]] (VIDO)  | Broadly Protective Coronavirus Vaccine  | Up to $5 million USD  | Protein subunit technology (preclinical)  |
| [[pharmaceutical_companies:Affinivax]]  | Broadly Protective Coronavirus Vaccine  | Up to $4.5 million USD  | [[Multiple Antigen Presenting System]] (MAPS) technology (preclinical)  |
| [[Translational Health Science and Technology Institute]] (THSTI), [[pharmaceutical_companies:Panacea Biotec]]  | Broadly Protective Coronavirus Vaccine  | Up to $12.5 million USD  | Nanoparticle vaccine platform (preclinical)  |
| [[pharmaceutical_companies:BioNet]]  | Broadly protective coronavirus vaccine  | Up to $16.9 million USD  | Nucleic acid (preclinical)  |
| [[pharmaceutical_companies:DIOSynVax]]  | Broadly protective coronavirus vaccine  | Up to $42 million USD  | Nucleic acid (preclinical)  |
| [[pharmaceutical_companies:NEC Corporation]]  | Broadly protective coronavirus vaccine  | Up to $4.8 million USD  | Nucleic acid (preclinical)  |
| [[pharmaceutical_companies:Gritstone bio]]  | COVID-19  | Up to $25.6 million USD  | Phase 1  |
| [[pharmaceutical_companies:Shanghai Zerun Biotechnology]]  | COVID-19  | Up to $25.1 million USD (funding discontinued)  | Chimeric protein vaccine (Phase 1)  |
| [[pharmaceutical_companies:VBI Vaccines]]  | COVID-19  | Up to $33 million USD  | [[Enveloped virus like particle]] (eVLP) (Phase 1)  |
| [[pharmaceutical_companies:Biological E. Limited]]  | COVID-19  | Up to $5 million USD  | Protein antigen (approved in [[India]])  |
| [[International Vaccine Institute]], [[pharmaceutical_companies:Bharat Biotech]]  | [[Chikungunya]]  | Up to $14.1 million USD  | Inactivated whole virion vaccine  (Phase 2/3)  |
| [[pharmaceutical_companies:Auro Vaccines]], [[PATH]]  | [[Nipah virus]]  | Up to $25 million USD  | HeV-sG-V vaccine (Phase 1)  |
| [[pharmaceutical_companies:Clover Biopharmaceuticals]]  | COVID-19  | Up to $397.4 million USD  | S-Trimer vaccine (Phase 2/3)  |
| [[Pasteur Institute]], [[pharmaceutical_companies:Themis Bioscience]], [[University of Pittsburgh]]  | COVID-19  | Up to $4.9 million USD  | [[Measles vector]] (development discontinued)  |
| [[University of Hong Kong]]  | COVID-19  | Up to $5.4 million USD  | Live attenuated vaccine (Phase 1)  |
| [[pharmaceutical_companies:Novavax]]  | COVID-19  | Up to $399 million USD  | Recombinant protein nanoparticle technology (Phase 3)  |
| [[University of Oxford]], [[pharmaceutical_companies:AstraZeneca]]  | COVID-19  | Up to $384 million USD  | [[covid-19_vaccines:vaxzevria|ChAdOx1 nCoV-19]]  (Phase 3)  |
| [[University of Queensland]]  | COVID-19  | Up to $4.5 million USD (funding discontinued)  | Recombinant protein (development discontinued)  |
| University of Queensland  | [[mers_cov|MERS coronavirus]]  | Up to $10.6 million USD  | Recombinant protein (preclinical)  |
| [[pharmaceutical_companies:Moderna]]  | COVID-19  | Up to $1 million USD  | Nucleic acid (Phase 3)  |
| [[pharmaceutical_companies:Inovio Pharmaceuticals]]  | COVID-19  | Up to $22.5 million USD  | Nucleic acid (Phase 2/3)  |
| Inovio Pharmaceuticals  | [[Lassa virus]]  | Up to $56 million USD (joint funding with Inovio's MERS vaccine)  | Nucleic acid (Phase 1)  |
| Inovio Pharmaceuticals  | MERS coronavirus  | -  | Nucleic acid (Phase 2)  |
| [[pharmaceutical_companies:CureVac]]  | COVID-19  | Up to $15.3 million USD  | Nucleic acid (development discontinued)  |
| CureVac  | Lassa virus  | Up to $34 million USD  | Nucleic acid (preclinical)  |
| [[pharmaceutical_companies:Public Health Vaccines]]  | Nipah virus  | Up to $43.6 million USD  | Recombinant [[viral vector]] (Phase 1)  |
| [[pharmaceutical_companies:Valneva]]  | Chikungunya  | Up to $23.4 million USD  | Live attenuated vaccine (Phase 3)  |
| [[Colorado State University]]  | [[Rift Valley Fever]]  | Up to $9.5 million USD  | Live attenuated vaccine (preclinical)  |
| [[pharmaceutical_companies:Emergent BioSolutions]], [[PATH]]  | Lassa virus  | Up to $36 million USD  | Recombinant viral vector (Phase 1)  |
| [[Wageningen Bioveterinary Research]]  | Rift Valley Fever  | Up to $12.5 million USD  | Live attenuated vaccine (preclinical)  |
| [[University of Tokyo]]  | Nipah virus  | Up to $31 million USD  | Recombinant viral vector (preclinical)  |
| [[International AIDS Vaccine Initiative]] (IAVI)  | Lassa virus  | Up to $64.4 million USD  | Recombinant viral vector (Phase 1)  |
| Themis Bioscience  | Lassa virus  | Up to $37.5 million USD (joint funding with Themis' MERS vaccine)  | Recombinant viral vector (Phase 1)  |
| Themis Bioscience  | MERS coronavirus  | -  | Recombinant viral vector (preclinical)  |
| Themis Bioscience  | Chikungunya  | Up to $21 million USD  | Recombinant viral vector (preparing for Phase 3)  |
| [[pharmaceutical_companies:IDT Biologika]]  | MERS coronavirus  | Up to $36 million USD  | Recombinant viral vector (preclinical)  |
| [[pharmaceutical_companies:Janssen]], [[University of Oxford]]  | Lassa virus  | Up to $19 million USD for Janssen's Lassa, MERS, Nipah vaccines  | Recombinant viral vector (preclinical)  |
| Janssen, University of Oxford  | MERS coronavirus  | -  | Recombinant viral vector (preclinical)  |
| Janssen, University of Oxford  | Nipah virus  | -  | Recombinant viral vector (preclinical)  |
| [[Imperial College London]]  | [[Marburg virus]]  | Up to $8.4 million USD  | Nucleic acid (preclinical)  |
===== External links =====

  * [[https://en.wikipedia.org/wiki/Coalition_for_Epidemic_Preparedness_Innovations|Wikipedia]]
  * [[https://wiki.whiteroseintelligence.com/Coalition-for-Epidemic-Preparedness-Innovations|White Rose Wiki]]
  * [[https://wikispooks.com/wiki/Coalition_for_Epidemic_Preparedness_Innovations|Wikispooks]]